Pharmacological disease models
Small molecules and excitotoxic agents can be used to pharmacologically induce disease models such as epilepsy, Parkinson's Disease, catalepsy, Schizophrenia, pain and diabetes models. Researchers can save up to 50% on excitotoxic agents - they are up to half the price of other suppliers.
D-AP5 (HB0225)
Description:Selective, competitive NMDA receptor antagonist. Inhibits NMDAR-synaptic plasticity.
Purity:>99%
L-Ascorbic acid (HB1238)
Description:Antioxidant. Enhances iPSC generation and increases reprogramming efficiency. Supports mesenchymal stem cell proliferation.
Purity:>99%
Bafilomycin A1 (HB1125)
Description:Highly potent, selective V-ATPase inhibitor. Autophagy inhibitor.
Purity:>98%
Brefeldin A (BFA) (HB2949)
Description:Reversible protein transport inhibitor. Commonly used in cytokine staining. Enhances CRISPR-mediated HDR.
Purity:>98%
- Description:
Fluorescent β2 adrenoceptor antagonist
Caffeine (HB2846)
Description:Non-selective, competitive adenosine receptor antagonist / PDE inhibitor
Calphostin C (HB0160)
Description:Potent, selective PKC inhibitor. Also antagonizes the Tcf/β-catenin complex
Purity:>95%
Calyculin A (HB0161)
Description:Potent, selective protein phosphatase 1 / 2A inhibitor
Purity:>98%
(S)-4-Carboxyphenylglycine (HB0049)
Description:Competitive, selective group 1 mGlu antagonist
Purity:>99%